Navigation Links
GrantAdler Shipping Novel Implantable Vascular Access Port
Date:9/21/2007

NAPERVILLE, Ill., Sept. 21 /PRNewswire/ -- Designed by a surgeon, the revolutionary new GrantAdler(R) Rhapsody(TM) vascular access system simplifies and speeds vascular access port implantation. The Rhapsody system addresses four key problems with traditional ports:

1) Time-consuming catheter sizing and adjustment

2) Catheter kinking, pinch-off, and breakage

3) Assembly problems with the small clips and locks used with other port

systems

4) Catheter detachment from the port body

(Photo: http://www.newscom.com/cgi-bin/prnh/20070921/AQF039)

"When clinicians first see Rhapsody, they immediately recognize the innovative ease of use features and time saving advantages engineered into this novel access port system," said Mike Loiterman, GrantAdler's CEO. "They also see the significant clinical benefits of its fracture resistant catheter. The Rhapsody system also incorporates a dramatically improved catheter-to-port coupling system, which tests have shown to be 30% stronger than competitive systems. The clear benefits of these features have led to rapid market acceptance that meet the company's sales growth targets."

A number of clinician-friendly features make Rhapsody the easiest vascular access port to implant. During the procedure, the physician simply selects the short, medium, or long pre-cut catheter based on the patient's anatomy and an actual measurement shown on a special guide wire that is included in the system's tray.

A reinforcing coil embedded in the wall of GrantAdler's unique catheter reduces the chance for kinking, pinch-off, and fracture, while maintaining great flexibility. This metal reinforcement allows the very robust thin-wall catheter to have both an inside diameter (ID) of 2 mm (the largest in the industry) and a very small 7.5 Fr (2.475 mm) outside diameter (OD). The large ID allows unrestricted high flow
'/>"/>

SOURCE GrantAdler
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Gene enchances radiation therapy - A novel approach to fight cancer
3. A novel augmentation
4. Novel biopsy technique for prostate cancer
5. Novel computer model for breast cancer
6. Novel research on liver cancer
7. Novel way to fight cancer
8. Novel test for bowel cancer
9. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
10. Novel Therapy for Chronic Problem
11. Blood Sugar Kept In Control By Novel Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)... MONROVIA, Calif., July 24 /PRNewswire-FirstC... leading developer, manufacturer and marketer of,m...nced that the Centers,for Medicare and Medicaid Se...heric cataract lenses as New Technology Intraocula...amer(R) Aspheric Single Piece foldable,intraocular...
(Date:7/24/2008)... Ground-breaking Technology Debuts in the Trance... Shoe, BOTHELL, Wash., July 24 /PRNewswi...Sports, Inc. today announced that BioMoGo, the wor... to consumers in the new Trance(TM),8 premium supp... times,faster than conventional athletic shoe mids...
(Date:7/24/2008)... NEW YORK, July 24 /PRNewswire/ -- MS -- Toda...nt things. For those who care for their,bodies, by...ations for,anti-aging, it is possible to feel and ...http://www.newscom.com/cgi-bin/prnh/20080724/NYFNS...uthor, and frequent guest on,Oprah Winfrey,s progr...
(Date:7/24/2008)... SCHAUMBURG, Ill., July 24 /PRNewswire/ -- A ...America,s most chronic problems -- obesity -- in,p... weight problem. About one third of us are,obese, ...ets -- they really,do look like us -- mirror us wi...esity, a public/private partnership that includes,...
Breaking Medicine News(10 mins):Health News:STAAR Surgical's Collamer(R) IOL and Elastimide(R) IOL Each Recognized with New Technology Intraocular Lens Classification 2Health News:STAAR Surgical's Collamer(R) IOL and Elastimide(R) IOL Each Recognized with New Technology Intraocular Lens Classification 3Health News:STAAR Surgical's Collamer(R) IOL and Elastimide(R) IOL Each Recognized with New Technology Intraocular Lens Classification 4Health News:Brooks(R) Sports Launches BioMoGo Biodegradable Shoe 2Health News:Brooks(R) Sports Launches BioMoGo Biodegradable Shoe 3Health News:Live to 100 ... And Feel Great 2Health News:PetFit Challenge Helps Keep Pets - and Pet Owners - Healthy 2
...ndia has declined over the century from 972 in 190... to 933 in 2001. In contrast, the child sex rati...rls per thousand boys against 945 recorded in 1991...tio is concerned, it is 1.01 male (s)/females as i...
...ntessentially Indian puff, has become a victim of ...outhern districts of Tamil Nadu going on strike. ...wrapped in leaf, from Tirunelveli, Tuticorin and K...this weekend to protest the union health ministry ...
...Democratic Front (LDF) government, set to mark its...at it is to blame for the deaths of 38 newborns in...fection in the labour room of the Sree Avittam Tir...the last two months. A court has charged Health M...
...is of concern as it is a reflection of the prevale...s and the extent of transmission of TB infection ...orted under the programme are of paediatric age gr...ntage of paediatric cases reported at national lev...
Other Medicine News:Health News:Bidi Workers Protest Against Using Skull and Crossbones Sign on Packets 2
(Date:7/23/2008)...py to Treat the Disease -, WAYNE, N.J. and EMERYV...yer HealthCare Pharmaceuticals and Onyx Pharmaceut...e New England Journal of Medicine published,result... (sorafenib),tablets decreased the absolute risk o...e hepatocellular carcinoma (HCC), or liver cancer,...
(Date:7/23/2008).../ -- The following was,released by the U.S. Depart...r Smith, and Members of the Committee.,Thank you f...eared before this Committee almost six months ago,...ented and dedicated professionals,at the Justice D...me to,appreciate that much more deeply their servi...
(Date:7/23/2008)...ode BioPharmaceutics, Inc.,an emerging biopharmac...results demonstrating the utility of their lead dr...hronic blood disorder paroxysmal nocturnal,hemoglo...ted at the XXII,International Complement Workshop ...nly treatment currently available for PNH patients...
(Date:7/22/2008)...irstCall/ -- Following a,thorough review that conc...uticals Limited (ASX: PGL; Nasdaq: PGLA) today ann...study in liver cancer. Progen confirmed,its strate... compounds and,the company will actively seek to a...ugh Merger & Acquisition activity., The strategic...
Breaking Medicine Technology:The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen 28R 29 Technology at Lower Doses 1558 1Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen 28R 29 Technology at Lower Doses 1558 2Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen 28R 29 Technology at Lower Doses 1558 3Varian Announces Global Clinical Council to Develop RapidArc 28TM 29 Cancer Treatments 14693 1Varian Announces Global Clinical Council to Develop RapidArc 28TM 29 Cancer Treatments 14693 2Varian Announces Global Clinical Council to Develop RapidArc 28TM 29 Cancer Treatments 14693 3Varian Announces Global Clinical Council to Develop RapidArc 28TM 29 Cancer Treatments 14693 4Varian Announces Global Clinical Council to Develop RapidArc 28TM 29 Cancer Treatments 14693 5National Parkinson Foundation Announces Its New President and CEO 14689 1National Parkinson Foundation Announces Its New President and CEO 14689 2National Parkinson Foundation Announces Its New President and CEO 14689 3Michigan State Medical Society Will Present How VEBA is Shifting Michigans Health Care Gears 14686 1
... -- Additional Findings Reported Safety & Tole...and Healthy Subjects --, CHICAGO, June 25, 2007 /P...his week at the annual meeting of the American Dia...n inhibitor of,dipeptidyl-peptidase-4 (DPP-4) in d...raZeneca , in combination with metformin,exhibite...
... ,Focus On AV411,s Unique Mechanism of Action an...l Conditions , ALAMEDA, Calif., June 26, 2007 (PRI...harmaceutical company innovating therapeutics,for ...d today that,Expert Opinion on Investigational Dru...eline product, AV411 (ibudilast), a potential,firs...
Other Medicine Technology:Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 2Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 3Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 4Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 5Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 6Expert Opinion Highlights Avigen's AV411 as Potential New,Therapeutic for Neuropathic Pain and Opioid Withdrawal 2Expert Opinion Highlights Avigen's AV411 as Potential New,Therapeutic for Neuropathic Pain and Opioid Withdrawal 3Expert Opinion Highlights Avigen's AV411 as Potential New,Therapeutic for Neuropathic Pain and Opioid Withdrawal 4Expert Opinion Highlights Avigen's AV411 as Potential New,Therapeutic for Neuropathic Pain and Opioid Withdrawal 5
Anti Gliadin IgA Enzyme Immunosay for quantitative determination of Gliadin-IgG antibodies in serum.
...igned as a high throughput primary or backup instr...r offers performance and reliability equal to or g...advanced technology of the AUTION JET AJ-4270 and ...ate results, limiting interference from elevated p...
Assay uses highly specific rabbit anti-estriol antibody reparation - negligible cross-reactivity with other estrogen metabolites. Excellent assay precision and reproducibility. Superior sensitivity
...rone Sulfate (E1S) is the most abundant circulatin... men [1,2]. Estrone Sulfate is a major metabolite ...fe in blood [2,3]. In premenopausal women, estrone...e and estradiol, rising gradually during the folli...
Medicine Products: